Loomis, Sayles & Company
TEVA icon

Loomis, Sayles & Company’s Teva Pharmaceuticals TEVA Stock Holding History

Loomis, Sayles & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,134,115
Closed -$22.9M – 751
2025
Q3 		$22.9M Buy
1,134,115
+89,123
+9% +$1.57M 0.03% 217
2025
Q2 		$17.5M Buy
+1,044,992
New +$16.9M 0.02% 262
2017
Q1 		– Sell
-1,170,319
Closed -$42.4M – 1037
2016
Q4 		$42.4M Buy
1,170,319
+145,365
+14% +$5.8M 0.1% 125
2016
Q3 		$47.2M Sell
1,024,954
-8,626
-0.8% -$450K 0.12% 98
2016
Q2 		$51.9M Sell
1,033,580
-55,425
-5% -$2.95M 0.14% 92
2016
Q1 		$58.3M Buy
1,089,005
+98,352
+10% +$5.77M 0.17% 84
2015
Q4 		$65M Buy
990,653
+68,357
+7% +$4.22M 0.18% 76
2015
Q3 		$52.1M Sell
922,296
-104,941
-10% -$6.8M 0.15% 101
2015
Q2 		$60.7M Sell
1,027,237
-61,141
-6% -$3.77M 0.17% 107
2015
Q1 		$67.8M Buy
1,088,378
+36,257
+3% +$2.11M 0.19% 101
2014
Q4 		$60.5M Sell
1,052,121
-141,161
-12% -$7.86M 0.17% 117
2014
Q3 		$64.1M Buy
1,193,282
+108,253
+10% +$5.74M 0.19% 113
2014
Q2 		$56.9M Buy
1,085,029
+437,833
+68% +$22.4M 0.16% 137
2014
Q1 		$34.2M Buy
647,196
+644,908
+28,187% +$29.8M 0.1% 202
2013
Q4 		$92K Hold
2,288
– – ﹤0.01% 698
2013
Q3 		$86K Hold
2,288
– – ﹤0.01% 683
2013
Q2 		$90K Buy
+2,288
New +$89.1K ﹤0.01% 678

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Loomis, Sayles & Company's TEVA Position: Q4 2025 in Review

Loomis, Sayles & Company sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 1,134,115 shares — an estimated $22.9M sold.

Loomis, Sayles & Company first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $67.8M in Q1 2015. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Loomis, Sayles & Company reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,134,115 Teva Pharmaceuticals shares in Q4 2025, an estimated $22.9M.
  • Loomis, Sayles & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Loomis, Sayles & Company's Teva Pharmaceuticals position peaked at $67.8M in Q1 2015.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Loomis, Sayles & Company's 13F filing for Q4 2025, filed 12 Feb 2026.